Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE (PAR: OSE) introduces ‘Cis-Demasking’ technology
Published by Arron Aatkar, PhD

OSE has announced the presentation of its new proprietary ‘Cis-Demasking’ bispecific technology called OSE-CYTOMASK, for the design of novel cytokine drugs. OSE-CYTOMASK is a non-cleavable linker technology intended to generate regulated and targeted cytokine therapeutics for the delivery of highly active medicines with improved therapeutic indexes. Management will be presenting further details about OSE-CYTOMASK at a series of upcoming conferences, discussing its preclinical programmes based on an anti-PD1 masked cytokine (IL-2, IL-15), with conditional Cis-Demasking and Cis-Potentiation of tumour-specific T cells expressing PD1 or other immune targe targets.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.